Abstract
Sixteen patients with primary hypertriglyceridemia were treated, according to a double-blind crossover design, with acipimox 250 mg twice daily for one month and with acipimox 500 mg once daily for another month. The two treatments were separated by a one-month washout period. Serum triglycerides fell by 34% after both treatment periods. Apoprotein B decreased by 16% after acipimox 250 mg twice daily and by 24% after acipimox 500 mg once daily. Whole serum cholesterol significantly decreased only after acipimox 500 mg once daily and showed a trend toward a diminution after the other treatment period. High-density lipoprotein cholesterol and apoprotein A-I did not show significant changes. The comparison of the mean changes in serum lipids and apoprotein B during the two treatment periods failed to demonstrate significant differences. The lipid lowering activity of acipimox 500 mg a day was similar when the drug was taken in a single dose or in two divided doses.
| Original language | English |
|---|---|
| Pages (from-to) | 540-546 |
| Number of pages | 7 |
| Journal | Current Therapeutic Research |
| Volume | 46 |
| Issue number | 3 |
| Publication status | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Acipimox once daily in the treatment of primary hypertriglyceridemia. / Branchi, A.; Sommariva, D.; Rovellini, A.; Scapellato, L.; Lavezzari, M.; Fasoli, A.
In: Current Therapeutic Research, Vol. 46, No. 3, 1989, p. 540-546.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Acipimox once daily in the treatment of primary hypertriglyceridemia
AU - Branchi, A.
AU - Sommariva, D.
AU - Rovellini, A.
AU - Scapellato, L.
AU - Lavezzari, M.
AU - Fasoli, A.
PY - 1989
Y1 - 1989
N2 - Sixteen patients with primary hypertriglyceridemia were treated, according to a double-blind crossover design, with acipimox 250 mg twice daily for one month and with acipimox 500 mg once daily for another month. The two treatments were separated by a one-month washout period. Serum triglycerides fell by 34% after both treatment periods. Apoprotein B decreased by 16% after acipimox 250 mg twice daily and by 24% after acipimox 500 mg once daily. Whole serum cholesterol significantly decreased only after acipimox 500 mg once daily and showed a trend toward a diminution after the other treatment period. High-density lipoprotein cholesterol and apoprotein A-I did not show significant changes. The comparison of the mean changes in serum lipids and apoprotein B during the two treatment periods failed to demonstrate significant differences. The lipid lowering activity of acipimox 500 mg a day was similar when the drug was taken in a single dose or in two divided doses.
AB - Sixteen patients with primary hypertriglyceridemia were treated, according to a double-blind crossover design, with acipimox 250 mg twice daily for one month and with acipimox 500 mg once daily for another month. The two treatments were separated by a one-month washout period. Serum triglycerides fell by 34% after both treatment periods. Apoprotein B decreased by 16% after acipimox 250 mg twice daily and by 24% after acipimox 500 mg once daily. Whole serum cholesterol significantly decreased only after acipimox 500 mg once daily and showed a trend toward a diminution after the other treatment period. High-density lipoprotein cholesterol and apoprotein A-I did not show significant changes. The comparison of the mean changes in serum lipids and apoprotein B during the two treatment periods failed to demonstrate significant differences. The lipid lowering activity of acipimox 500 mg a day was similar when the drug was taken in a single dose or in two divided doses.
UR - http://www.scopus.com/inward/record.url?scp=0024442857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024442857&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0024442857
VL - 46
SP - 540
EP - 546
JO - Current Therapeutic Research - Clinical and Experimental
JF - Current Therapeutic Research - Clinical and Experimental
SN - 0011-393X
IS - 3
ER -